logo
Meta spending big on AI talent but will it pay off?

Meta spending big on AI talent but will it pay off?

CTV News21 hours ago

Mark Zuckerberg and Meta are spending billions of dollars for top talent to make up ground in the generative artificial intelligence race, sparking doubt about the wisdom of the spree.
OpenAI boss Sam Altman recently lamented that Meta has offered $100 million bonuses to engineers who jump to Zuckerberg's ship, where hefty salaries await.
A few OpenAI employees have reportedly taken Meta up on the offer, joining Scale AI founder and former chief executive Alexandr Wang at the Menlo Park-based tech titan.
Meta paid more than $14 billion for a 49 percent stake in Scale AI in mid-June, bringing Wang on board as part of the deal.
Scale AI labels data to better train AI models for businesses, governments and labs.
'Meta has finalized our strategic partnership and investment in Scale AI,' a Meta spokesperson told AFP.
'As part of this, we will deepen the work we do together producing data for AI models and Alexandr Wang will join Meta to work on our superintelligence efforts.'
US media outlets have reported that Meta's recruitment effort has also targeted OpenAI co-founder Ilya Sutskever; Google rival Perplexity AI, and hot AI video startup Runway.
Meta chief Zuckerberg is reported to have sounded the charge himself due to worries Meta is lagging rivals in the generative AI race.
The latest version of Meta AI model Llama finished behind its heavyweight rivals in code writing rankings at an LM Arena platform that lets users evaluate the technology.
Meta is integrating recruits into a new team dedicated to developing 'superintelligence,' or AI that outperforms people when it comes to thinking and understanding.
'Mercenary'
Tech blogger Zvi Moshowitz felt Zuckerberg had to do something about the situation, expecting Meta to succeed in attracting hot talent but questioning how well it will pay off.
'There are some extreme downsides to going pure mercenary... and being a company with products no one wants to work on,' Moshowitz told AFP.
'I don't expect it to work, but I suppose Llama will suck less.'
While Meta's share price is nearing a new high with the overall value of the company approaching $2 trillion, some investors have started to worry.
Institutional investors are concerned about how well Meta is managing its cash flow and reserves, according to Baird strategist Ted Mortonson.
'Right now, there are no checks and balances' with Zuckerberg free to do as he wishes running Meta, Mortonson noted.
The potential for Meta to cash in by using AI to rev its lucrative online advertising machine has strong appeal but 'people have a real big concern about spending,' said Mortonson.
Meta executives have laid out a vision of using AI to streamline the ad process from easy creation to smarter targeting, bypassing creative agencies and providing a turnkey solution to brands.
AI talent hires are a long-term investment unlikely to impact Meta's profitability in the immediate future, according to CFRA analyst Angelo Zino.
'But still, you need those people on board now and to invest aggressively to be ready for that phase' of generative AI, Zino said.
According to The New York Times, Zuckerberg is considering shifting away from Meta's Llama, perhaps even using competing AI models instead.
Penn State University professor Mehmet Canayaz sees potential for Meta to succeed with AI agents tailored to specific tasks at its platform, not requiring the best large language model.
'Even firms without the most advanced LLMs, like Meta, can succeed as long as their models perform well within their specific market segment,' Canayaz said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Infection Control Market to Reach USD 139.94 Billion by 2030, Driven by Hospital-Acquired Infection Prevention and Sterilization Demand
Infection Control Market to Reach USD 139.94 Billion by 2030, Driven by Hospital-Acquired Infection Prevention and Sterilization Demand

Globe and Mail

time12 minutes ago

  • Globe and Mail

Infection Control Market to Reach USD 139.94 Billion by 2030, Driven by Hospital-Acquired Infection Prevention and Sterilization Demand

"Infection Control Market" Mordor Intelligence has published a new report on the Infection Control Market offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction According to a 2025 report on infection control market by Mordor Intelligence, the market is estimated at USD 102.36 billion in 2025 and is projected to reach USD 139.94 billion by 2030, growing at a CAGR of 6.45% during the forecast period The infection control market plays a crucial role in maintaining hygiene and safety standards across hospitals, laboratories, pharmaceutical production units, and life sciences facilities. Infection prevention solutions such as sterilization, disinfection, and cleaning consumables are critical to minimize risks to patients, healthcare staff, and consumers. The market growth is attributed to rising hospital-acquired infection cases, stringent guidelines to control contamination, and high demand for effective sterilization products in medical device reprocessing. Key Trends Hospital-acquired infections driving product demand The report highlights that the increasing number of hospital-acquired infections (HAIs) has made infection control a critical operational area in hospitals and clinics. These infections prolong hospital stays and increase treatment costs, making preventive sterilization, disinfectant usage, and effective waste disposal mandatory to maintain public health standards. Sterilization segment maintains dominance Sterilization remains the largest segment in the infection control market, supported by the widespread use of sterilizers in hospitals, outpatient facilities, and diagnostic labs for surgical instrument reprocessing and equipment sterilization. Within sterilization, the use of low-temperature sterilizers is increasing to protect heat-sensitive instruments. Disinfectants witnessing rising application Disinfectants are used extensively for surface cleaning, floor cleaning, and equipment cleaning in critical care units and operating theatres. The trend of ready-to-use disinfectant wipes, sprays, and solutions is growing due to convenience and time efficiency in hospitals and diagnostic centres. Pharmaceutical and life sciences sector driving demand Beyond hospitals, pharmaceutical manufacturing units, research laboratories, and biotechnology firms require advanced contamination control. The demand for cleanrooms and sterile processing areas contributes significantly to market expansion in the infection control segment. North America remains the largest market According to the Mordor Intelligence report, North America continues to hold the largest market share driven by the high number of surgeries performed annually, better healthcare infrastructure, and stringent infection control regulations by organizations such as the CDC and FDA. Market Segmentation The infection control market report segments the industry into Product, Service Delivery Mode, End User and Geography. By Product Sterilization Products and Services: Includes equipment such as autoclaves and low-temperature sterilizers, along with contract sterilization services. These solutions ensure medical devices and surgical instruments are free from viable microorganisms before reuse. Cleaning and Disinfection Products: Encompasses disinfectant liquids, sprays, wipes, and detergents used for cleaning surfaces, instruments, and hospital environments to reduce contamination risks. Protective Barriers: Includes gloves, gowns, face masks, and drapes used by healthcare professionals to prevent cross-contamination during surgical or diagnostic procedures. By Service Delivery Mode In-house Infection Control: Refers to infection prevention and control activities managed within healthcare facilities, pharmaceutical manufacturing units, and laboratories using their own sterilization equipment, disinfectants, and staff. Hospitals and large medical centres often maintain in-house sterilization departments to handle equipment reprocessing and facility hygiene efficiently without outsourcing. Contract Infection Control: Outsourcing sterilization and contamination control services to third-party providers. This is widely used by medical device manufacturers and pharmaceutical companies that require large-scale sterilization but prefer specialized contract service providers to ensure regulatory compliance, cost efficiency, and access to advanced sterilization technologies without heavy capital investments. Hospitals and Clinics: The largest segment, driven by the constant need for sterilization and disinfection in surgical theatres, ICUs, OPDs, and diagnostic labs to prevent healthcare-associated infections. Medical Device Companies: Use sterilization services and equipment for manufacturing sterile medical products and packaging to comply with international quality and safety standards. Pharmaceutical and Life Sciences Companies: Require stringent contamination control and sterilization solutions in production lines, cleanrooms, and research facilities to ensure product safety and regulatory compliance. Pharmaceutical and Biologics Manufacturers: These include companies involved in producing pharmaceutical drugs, vaccines, and biologic products. They require stringent sterilization, contamination control, and cleanroom hygiene practices throughout manufacturing to ensure product safety, efficacy, and compliance with global regulatory standards. Life-Science and Food-Processing Facilities: Facilities engaged in life sciences research, diagnostics, and food processing depend on infection control measures to maintain sterile environments, prevent cross-contamination, and uphold product quality and safety during processing, packaging, and storage operations. Ambulatory Surgery Centers: These are outpatient surgical facilities that perform procedures not requiring hospital admission. Infection control practices such as equipment sterilization, use of disinfectants, and protective barriers are critical to ensure patient safety and prevent surgical site infections in these high-throughput environments. By Geography North America: Largest market with well-established infection control guidelines. Europe: Growing due to increased healthcare spending and focus on patient safety. Asia-Pacific: Expected to witness the fastest growth owing to rising surgical procedures, healthcare infrastructure development, and increasing awareness. Middle East & Africa: Growth driven by improving healthcare systems and infection prevention investments. South America: Developing market with gradual adoption of stringent infection control standards. Key Players The infection control market report identifies key companies providing sterilization, disinfection, and protective barrier solutions. Fortive (Advanced Sterilization Products): Advanced Sterilization Products (ASP) is a part of Fortive Corporation. ASP is known for providing infection prevention solutions, particularly focusing on sterilization and disinfection products used in hospitals and healthcare facilities. 3M Company: Offers a wide range of infection prevention products including sterilization assurance, hand hygiene, and barrier solutions catering to hospitals globally. Steris Corporation: Known for its sterilization equipment, instrument reprocessing products, and infection prevention consumables for healthcare and life sciences sectors. Getinge AB: Provides sterilizers, washer-disinfectors, and associated consumables with a strong market presence in hospital sterile processing departments. Cantel Medical Corp: Specializes in endoscope reprocessing systems, high-level disinfectants, and infection control consumables supporting GI and surgical care. These companies focus on expanding their infection prevention product portfolios through strategic acquisitions, product launches, and partnerships with hospitals, labs, and pharmaceutical companies to address growing infection control needs. Conclusion The infection control market is set for robust growth, with a projected value of USD 139.94 billion by 2030. Rising cases of hospital-acquired infections, expanding surgical procedures, and increasing contamination control requirements in pharmaceuticals and life sciences will continue to support market expansion. While North America remains dominant, Asia-Pacific is expected to witness the fastest growth in the coming years due to healthcare infrastructure development and heightened awareness regarding infection control practices. Companies investing in product innovation and strategic collaborations are well-positioned to meet evolving hospital, laboratory, and industrial hygiene demands. Industry Related Reports Dental Infection Control Market: The dental infection control market is segmented by Product Type (Equipment and Consumables), End User (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for these segments. Surgical Site Infection Control Market : Surgical Site Infection Control Market: is segmented by Product (Manual Preprocessors Solution, Disinfectants, and more), Surgery/Procedure (Cataract Surgery, Cesarean Section, and more), Type of Infection (Superficial Incisional SSI, and more), End User (Hospitals, and more), and Geography (North America, Europe, and more). The report provides the value (in USD million) for these segments. Get More Insights: Infection surveillance solutions market : Infection Surveillance Solutions Market is segmented by Type (Surgical-Site Infections, Blood-Stream Infections, Catheter-Associated UTIs, and Ventilator-Associated Pneumonia), Offering (Software and Services), Deployment Model (On-Premises and Cloud), End User (Hospitals, Long-Term Care Facilities, Ambulatory Surgery Centers, and more), and Geography. The report provides the market forecasts in terms of value (USD). About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@

Why Newsmax Stock Zoomed Almost 14% Higher Today
Why Newsmax Stock Zoomed Almost 14% Higher Today

Globe and Mail

time26 minutes ago

  • Globe and Mail

Why Newsmax Stock Zoomed Almost 14% Higher Today

Newsmax (NYSE: NMAX) reached a notable milestone in its brief existence as a publicly traded company on Monday, and investors reacted by snapping up shares of the stock. It closed the day nearly 14% higher in price, and with that performance absolutely thrashed the S&P 500 index's 0.5% gain. Maximizing visibility As of Monday, Newsmax is part of both the Russell 2000 and Russell 3000 indexes. At a stroke this makes the media stock a member of both a prominent small-cap equity tracker, as part of the former index, and a component of an index that includes the largest U.S. companies with the latter. Inclusion on (or exclusion from, while we're on the subject) an index has little if no direct effect on a company's operations and fundamentals. However there's the phenomenon of "the index effect," in which stocks can get pops simply from the free publicity and higher visibility that comes with joining a well-known index. To a degree, this is justified. The many index funds that sniff around Russell 2000, Russell 3000, or any one of the many other stock indexes always need to be invested in component stocks. Inclusion automatically makes a company a candidate for such institutional buyers, thereby raising demand for its stock to some extent. Remember what's important While Newsmax is surely glad and proud to be part of the two Russells, I should reiterate and emphasize that this development alone shouldn't sway investors toward or away from the company's stock. It's the fundamentals that ultimately matter, and at the end of the day Newsmax will sink or swim on them. Personally, I'm not captivated by its performance and I wouldn't buy the stock just now, although the business surely has potential. Should you invest $1,000 in Newsmax right now? Before you buy stock in Newsmax, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Newsmax wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store